ANDDI-PRENATOME - Feasibility Study for a " Fast " Pangenomic High Throughput Sequencing Analysis in Prenatal Diagnosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

149 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-20

Study Completion Date

2024-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prenatal diagnosis of genetic diseases is a real medical challenge. The discovery of antenatal abnormalities on ultrasound is frequent (5 to 10% of pregnancies), and when an abnormalities is seen on ultrasound, it raises the possibility of an underlying developmental anomaly. Currently, in France, when abnormalities are discovered with an ultrasound scan, the etiological diagnosis is based on additional imaging tests (cerebral MRI, 3D bone tomography, fetal CT, fetal CT) or diagnostic tests such as invasive chorionic villus sampling, amniocentesis or fetal blood for infectious, metabolic, immunological and genetic investigations (standard karyotype, FISH (fluorescence in situ hybridization) for the rapid detection of aneuploidy, Chromosome Analysis on DNA Chip (ACPA or CGH-array) and possible sequencing of targeted genes when they are available within a time frame compatible with pregnancy). NIPT (Non-invasive prenatal testing) on cell free fetal DNA circulating in maternal blood has more limited indications, allowing, from an early stage of pregnancy, the determination of fetal sex and fetal rhesus factor and the search for aneuploidy.

However, establishing an etiological diagnosis during pregnancy has many benefits for the parents: clarifying the cause, obtaining a more precise prognosis to determine future management and outcome of the pregnancy, and establishing the risks of recurrence.

Over the past decade, medical genetics has undergone a real technological revolution, leading to the development of high throughput genome-wide, exome (ES) and genome (GS) sequencing. However, few countries have currently embarked on ES/GS in prenatal care, due to the constraints of time and the difficulty of interpreting genomic data when the clinical data is limited to antenatal imaging data.

In 2016, France launched the France Medicine Genomics 2025 Plan (PFMG2025) to deploy GS, particularly in the diagnosis of rare diseases. It is thus becoming essential to define the modalities of prescription of this testing, in particular during prenatal diagnosis. In parallel, from the first publications, the applications of genomic analysis on circulating fetal DNA seem to be able to extend to genome sequencing for research of SNVs responsible for developmental diseases.

The AnDDI-rares health network therefore proposes this ANDDI-PRENATOME pilot project to study the feasibility of a "rapid" analysis of ES in prenatal diagnosis from 61 fetuses with ultrasound abnormalities, as a first step before considering future cost-effectiveness (PRME) or care system performance (PREPS) studies in conjunction with the PFMG2025.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Realization of Sequencing of All Known Human Genes in Case of Detection of Cerebral, Renal or Ophthalmological Fetal Malformations During Pregnancy in Order to Make an Etiological Diagnosis and to Precise the Fetal Prognosis

NCT04406480

Fetal Malformation Pregnancy Related Rare Genetic Disease

UNKNOWN NA

Ultra-early Identification of Fetal Chromosomal Characteristics From Extravillous-trophoblast Cells

NCT06523543

Pregnant Women

RECRUITING

Prenatal Genetic Diagnosis by Genomic Sequencing

NCT03936101

Fetal Structural Anomalies

COMPLETED

PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood

NCT03831256

Prenatal Disorder Aneuploidy

ACTIVE_NOT_RECRUITING NA

Non Invasive Prenatal Test of Rare Genetic Diseases: Application to Rare Intellectual Disabilities

NCT03688594

Genetic Disorders in Pregnancy

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prenatal Genome-wide High Throughput Sequencing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control

fetus with at least 2 ultrasound abnormalities and both parents

Invasive fetal sampling, blood sampling of mother and father

Intervention Type BIOLOGICAL

to perform an exome sequencing analysis in trio

Parent interviews (optional organizational study)

Intervention Type OTHER

Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results

parent questionnaire (optional organizational study)

Intervention Type OTHER

To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results

comparison

fetus with at least 2 ultrasound abnormalities with ES diagnosis on invasive fetal sampling

Invasive fetal sampling, blood sampling of mother and father

Intervention Type BIOLOGICAL

to perform an exome sequencing analysis in trio

blood sampling from the mother to recover the circulating cell free fetal DNA

Intervention Type BIOLOGICAL

to perform a sequencing analysis of the genome of circulating free fetal DNA

Parent interviews (optional organizational study)

Intervention Type OTHER

Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results

parent questionnaire (optional organizational study)

Intervention Type OTHER

To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results

professional

obstetrician, midwife, geneticist, biologist

professional interviews (optional organizational study)

Intervention Type OTHER

interview to understand how the decision is formed

Focus group for professionals (optional organizational study)

Intervention Type OTHER

interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Invasive fetal sampling, blood sampling of mother and father

to perform an exome sequencing analysis in trio

Intervention Type BIOLOGICAL

blood sampling from the mother to recover the circulating cell free fetal DNA

to perform a sequencing analysis of the genome of circulating free fetal DNA

Intervention Type BIOLOGICAL

Parent interviews (optional organizational study)

Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results

Intervention Type OTHER

parent questionnaire (optional organizational study)

To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results

Intervention Type OTHER

professional interviews (optional organizational study)

interview to understand how the decision is formed

Intervention Type OTHER

Focus group for professionals (optional organizational study)

interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women with antenatal discovery of at least two obstetric ultrasound abnormalities (2 major malformations, or 1 major malformation and 1 minor malformation, or 1 isolated malformation with a high probability of a genetic condition) : who undergo invasive antenatal sampling for CGH-array diagnosis ; who has already had an invasive antenatal sampling for the diagnosis of CGH-array and for which the fetal CGH-array has been found to be normal (sufficient fetal DNA or amniotic fluid should be available to allow exome sequencing to be performed without further amniotic fluid puncture).
* Pregnant woman and father aged 18 years or more
* Written consent provided by the pregnant woman and the father of the fetus
* Possibility of sufficient fetal specimen (amniotic fluid or fetal blood) to collect an additional sample for the pilot project
* Possibility of sampling the pregnant woman and the father of the foetus (peripheral blood)
* Pregnant woman and father of the fetus able to understand the study

Pilot Organizational Study:

Exclusion Criteria

* Pregnant woman and biological father of fetus who provided oral consent to be interviewed
* Professionals (obstetrician, midwife, geneticist, biologist) agreeing to be interviewed

* Diagnostic hypothesis considered highly probable that can be confirmed by an available molecular or cytogenetic test with a lower cost than ES (e. g. 22q11 microdeletion) or high suspicion of fetal infection (e. g. toxoplamosis seroconversion)
* Refusal of pregnant woman or father of fetus to participate in the study
* Pregnancy earlier than 15 weeks of amenorrhea or later than 34 weeks of amenorrhea
* Pregnant woman and father of the foetus not covered by the national health insurance system
* Pregnant woman and/or father of the fetus under partial judicial protection

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No